Acute effects of an oral supplement of (−)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects

Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably mo...

Full description

Saved in:
Bibliographic Details
Published inFood & function Vol. 5; no. 3; pp. 521 - 527
Main Authors Gutiérrez-Salmeán, Gabriela, Ortiz-Vilchis, Pilar, Vacaseydel, Claudia M, Rubio-Gayosso, Ivan, Meaney, Eduardo, Villarreal, Francisco, Ramírez-Sánchez, Israel, Ceballos, Guillermo
Format Journal Article
LanguageEnglish
Published England 01.03.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg −1 ). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. (−)-Epicatechin modulates postprandial metabolism by enhancing fat oxidation.
AbstractList Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg/kg). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.
Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.
Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg −1 ). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. (−)-Epicatechin modulates postprandial metabolism by enhancing fat oxidation.
Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.
Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg⁻¹). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.
Author Rubio-Gayosso, Ivan
Ortiz-Vilchis, Pilar
Meaney, Eduardo
Villarreal, Francisco
Gutiérrez-Salmeán, Gabriela
Ramírez-Sánchez, Israel
Vacaseydel, Claudia M
Ceballos, Guillermo
AuthorAffiliation University of California San Diego
Instituto Politécnico Nacional
Department of Medicine
Escuela Superior de Medicina
Laboratorio de Investigación Integral Cardiometabólica
AuthorAffiliation_xml – name: Laboratorio de Investigación Integral Cardiometabólica
– name: University of California San Diego
– name: Escuela Superior de Medicina
– name: Instituto Politécnico Nacional
– name: Department of Medicine
– name: 2 University of California San Diego, Department of Medicine. La Jolla, CA, USA
– name: 1 Laboratorio de Investigación Integral Cardiometabólica. Escuela Superior de Medicina, Instituto Politécnico Nacional. México City, México
Author_xml – sequence: 1
  givenname: Gabriela
  surname: Gutiérrez-Salmeán
  fullname: Gutiérrez-Salmeán, Gabriela
– sequence: 2
  givenname: Pilar
  surname: Ortiz-Vilchis
  fullname: Ortiz-Vilchis, Pilar
– sequence: 3
  givenname: Claudia M
  surname: Vacaseydel
  fullname: Vacaseydel, Claudia M
– sequence: 4
  givenname: Ivan
  surname: Rubio-Gayosso
  fullname: Rubio-Gayosso, Ivan
– sequence: 5
  givenname: Eduardo
  surname: Meaney
  fullname: Meaney, Eduardo
– sequence: 6
  givenname: Francisco
  surname: Villarreal
  fullname: Villarreal, Francisco
– sequence: 7
  givenname: Israel
  surname: Ramírez-Sánchez
  fullname: Ramírez-Sánchez, Israel
– sequence: 8
  givenname: Guillermo
  surname: Ceballos
  fullname: Ceballos, Guillermo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24458104$$D View this record in MEDLINE/PubMed
BookMark eNqFks1OFjEUhhuDEUQ27jXjDklGO52Z_mxICBExIXGjibum7ZzyFWemY9vBcAeGJZfoldDJB59ijHbTpud53_PTPkVbox8BoecVflPhWrw1tfUUNxX9-gjtENyQkrb4y9b9uRF0G-3FeIHzqoXggj9B26RpWl7hZgddH5k5QQHWgkmx8LZQY-GD6os4T1MPA4xpud3_-ePmdQmTMyqBWbkMjcXkY5qCGjuXeatS1naFUUH71VUXMlgMkJT2vYtDkSWjD0MmF8pfQvgO7nyVciJ9sSR_hh5b1UfYu9t30eeTd5-OT8uzj-8_HB-dlabhIpWMsRpa2mqtBes4B00tq1jbGEENsRQ0pwAUKsWt7YBUBBhlWauM4sKyehcdrn2nWQ_Qmdxh7ldOwQ0qXEmvnHwYGd1KnvtLWYuGMUGywf6dQfDfZohJDi4a6Hs1gp-jJHWbB8zyhP-LVi0mQjBCeEZf_l7Wpp77t8rAwRowwccYwG6QCsvlL8hffyHD-A_YuKSS80tLrv-75MVaEqLZWD-Iv_pXXE6drW8BiybQoA
CitedBy_id crossref_primary_10_1016_j_freeradbiomed_2018_11_010
crossref_primary_10_3390_diseases4040039
crossref_primary_10_1016_j_clnu_2021_11_030
crossref_primary_10_1039_C9FO00918C
crossref_primary_10_1093_nutrit_nux028
crossref_primary_10_1016_j_jnutbio_2019_108296
crossref_primary_10_1055_a_1843_9855
crossref_primary_10_1155_2016_5630985
crossref_primary_10_3945_jn_115_215772
crossref_primary_10_3390_nu11020417
crossref_primary_10_1093_ajcn_nqy066
crossref_primary_10_3389_fphys_2015_00296
crossref_primary_10_1186_s12944_021_01487_9
crossref_primary_10_2478_s11756_019_00343_7
crossref_primary_10_1093_nutrit_nux070
crossref_primary_10_3390_antiox10030467
crossref_primary_10_3390_nu14061316
crossref_primary_10_1016_j_ijcard_2016_08_158
crossref_primary_10_1186_s41110_020_00118_0
crossref_primary_10_1016_j_freeradbiomed_2016_01_016
crossref_primary_10_1016_j_abb_2020_108505
crossref_primary_10_1051_e3sconf_202123302032
crossref_primary_10_3389_fnut_2018_00132
crossref_primary_10_1016_j_jff_2023_105751
crossref_primary_10_1089_jmf_2019_0201
crossref_primary_10_3390_cells10061346
crossref_primary_10_1039_C7FO01028A
crossref_primary_10_3390_nu13020571
crossref_primary_10_1016_j_heliyon_2019_e01512
crossref_primary_10_1007_s40496_024_00390_3
crossref_primary_10_31883_pjfns_131061
crossref_primary_10_3390_ijms17111877
crossref_primary_10_3390_nu15245136
crossref_primary_10_1039_C5FO00750J
crossref_primary_10_1016_j_jnutbio_2015_12_008
crossref_primary_10_3390_jcm13010195
crossref_primary_10_3390_sports8020022
crossref_primary_10_3390_nu12071902
crossref_primary_10_1007_s00424_021_02640_0
Cites_doi 10.1080/07315724.2007.10719627
10.4158/EP.13.S1.1
10.1021/jf0603681
10.4093/dmj.2011.35.4.404
10.1016/j.metabol.2008.06.014
10.1248/jhs.51.248
10.3109/17477166.2010.543684
10.1089/ars.2010.3697
10.3945/ajcn.112.040469
10.1016/j.brainresbull.2011.07.001
10.3390/nu2070737
10.2337/diabetes.51.2007.S258
10.1016/j.clinthera.2012.04.012
10.1111/j.1463-1326.2004.00407.x
10.1155/2011/676208
10.2337/dc09-2191
10.1016/j.nutres.2009.10.003
10.1038/ejcn.2010.47
10.4065/mcp.2010.0434
10.1517/14656566.7.8.1055
10.1093/gerona/glr235
10.1016/j.metabol.2011.06.008
10.1046/j.1365-201X.2003.01164.x
10.1093/ajcn/87.3.778
10.3109/09637486.2011.636346
10.1113/jphysiol.2011.209924
10.4162/nrp.2011.5.1.28
10.1038/ijo.2010.5
10.4158/EP.14.1.112
10.1017/S0007114511005083
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
DOI 10.1039/c3fo60416k
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE
AGRICOLA
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Diet & Clinical Nutrition
EISSN 2042-650X
EndPage 527
ExternalDocumentID PMC3947792
24458104
10_1039_c3fo60416k
c3fo60416k
Genre Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIMHD NIH HHS
  grantid: P60 MD000220
– fundername: NCCIH NIH HHS
  grantid: R21 AT004277
– fundername: NIMHD NIH HHS
  grantid: P60MD001
– fundername: NCCIH NIH HHS
  grantid: AT4277
– fundername: NIDDK NIH HHS
  grantid: DK98717
– fundername: NIDDK NIH HHS
  grantid: R24 DK092154
– fundername: NHLBI NIH HHS
  grantid: HL43617
– fundername: NHLBI NIH HHS
  grantid: R01 HL043617
GroupedDBID ---
0-7
0R~
4.4
53G
705
7~J
AAEMU
AAHBH
AAIWI
AAJAE
AANOJ
AARTK
AAWGC
AAXHV
AAYXX
ABASK
ABDVN
ABEMK
ABIQK
ABJNI
ABPDG
ABRYZ
ABXOH
ACGFS
ACLDK
ACPRK
ACRPL
ADMRA
ADNMO
ADSRN
AEFDR
AENEX
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRAH
AFRZK
AFVBQ
AGEGJ
AGQPQ
AGRSR
AHGCF
AHGXI
AKBGW
AKMSF
ALMA_UNASSIGNED_HOLDINGS
ALSGL
ANBJS
ANLMG
ANUXI
APEMP
ASKNT
ASPBG
AUDPV
AVWKF
AZFZN
BLAPV
BSQNT
C6K
CAG
CITATION
COF
EBS
ECGLT
EE0
EF-
EJD
FEDTE
GGIMP
H13
HVGLF
HZ~
H~N
J3G
J3H
J3I
L-8
O-G
O9-
P2P
RAOCF
RCNCU
RNS
RPMJG
RSCEA
RVUXY
SKF
SKH
SKJ
SKM
SKR
SKZ
SLC
SLF
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c489t-7773e565bbb97d88eb6f71754c96c2f6eb86ee6e1a8ffde212e767c48aca89f73
ISSN 2042-6496
2042-650X
IngestDate Thu Aug 21 13:43:22 EDT 2025
Fri Jul 11 12:31:00 EDT 2025
Fri Jul 11 11:55:00 EDT 2025
Mon Jul 21 05:55:04 EDT 2025
Tue Jul 01 02:37:31 EDT 2025
Thu Apr 24 23:08:31 EDT 2025
Thu May 19 04:20:30 EDT 2016
Thu May 30 17:43:46 EDT 2019
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c489t-7773e565bbb97d88eb6f71754c96c2f6eb86ee6e1a8ffde212e767c48aca89f73
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Drs. Ramírez-Sánchez and Ceballos co-senior this work
PMID 24458104
PQID 1502997228
PQPubID 23479
PageCount 7
ParticipantIDs crossref_citationtrail_10_1039_c3fo60416k
proquest_miscellaneous_1502997228
crossref_primary_10_1039_c3fo60416k
rsc_primary_c3fo60416k
proquest_miscellaneous_2352447581
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3947792
pubmed_primary_24458104
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-03-01
PublicationDateYYYYMMDD 2014-03-01
PublicationDate_xml – month: 03
  year: 2014
  text: 2014-03-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Food & function
PublicationTitleAlternate Food Funct
PublicationYear 2014
References O'Keefe (c3fo60416k-(cit3)/*[position()=1]) 2011; 86
Kurihara (c3fo60416k-(cit11)/*[position()=1]) 2006; 54
Ruderman (c3fo60416k-(cit28)/*[position()=1]) 2003; 178
Katz (c3fo60416k-(cit8)/*[position()=1]) 2011; 15
Chen (c3fo60416k-(cit14b)/*[position()=1]) 2009; 29
Briones (c3fo60416k-(cit5)/*[position()=1]) 2006; 7
Linderborg (c3fo60416k-(cit22a)/*[position()=1]) 2012; 63
Simon (c3fo60416k-(cit16)/*[position()=1]) 2002; 51
Ramos-Roman (c3fo60416k-(cit19)/*[position()=1]) 2012; 61
Mohamed (c3fo60416k-(cit9)/*[position()=1]) 2011; 86
Derosa (c3fo60416k-(cit7)/*[position()=1]) 2012; 34
Crandall (c3fo60416k-(cit24)/*[position()=1]) 2012; 67
Jang (c3fo60416k-(cit21a)/*[position()=1]) 2008; 57
Crisp (c3fo60416k-(cit18)/*[position()=1]) 2011; 6
James (c3fo60416k-(cit4)/*[position()=1]) 2005; 7
Nogueira (c3fo60416k-(cit14a)/*[position()=1]) 2011; 589
Lee (c3fo60416k-(cit15)/*[position()=1]) 2011; 35
Harada (c3fo60416k-(cit26)/*[position()=1]) 2005; 51
Okorodudu (c3fo60416k-(cit13)/*[position()=1]) 2010; 34
Murase (c3fo60416k-(cit22b)/*[position()=1]) 2012; 107
Rodbard (c3fo60416k-(cit17)/*[position()=1]) 2007; 13
Boschmann (c3fo60416k-(cit23)/*[position()=1]) 2007; 26
Arnolds (c3fo60416k-(cit6)/*[position()=1]) 2010; 33
De Gottardi (c3fo60416k-(cit10)/*[position()=1]) 2012; 96
Bell (c3fo60416k-(cit2)/*[position()=1]) 2008; 14
Aoi (c3fo60416k-(cit27)/*[position()=1]) 2011; 2011
Lee (c3fo60416k-(cit25)/*[position()=1]) 2011; 5
Thielecke (c3fo60416k-(cit12)/*[position()=1]) 2010; 64
Venables (c3fo60416k-(cit20)/*[position()=1]) 2008; 87
Meydani (c3fo60416k-(cit21b)/*[position()=1]) 2010; 2
22219517 - J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12
22098442 - Int J Food Sci Nutr. 2012 Jun;63(4):483-90
16722815 - Expert Opin Pharmacother. 2006 Jun;7(8):1055-64
21270290 - Mayo Clin Proc. 2011 Feb;86(2):128-38
22254051 - Nutrients. 2010 Jul;2(7):737-51
21244226 - Int J Pediatr Obes. 2011 Jun;6(2-2):e615-21
22811444 - Am J Clin Nutr. 2012 Sep;96(3):584-90
18940397 - Metabolism. 2008 Nov;57(11):1576-83
21773023 - J Nutr Metab. 2011;2011:676208
17613449 - Endocr Pract. 2007 May-Jun;13 Suppl 1:1-68
19932867 - Nutr Res. 2009 Nov;29(11):784-93
21788351 - J Physiol. 2011 Sep 15;589(Pt 18):4615-31
17906192 - J Am Coll Nutr. 2007 Aug;26(4):389S-395S
16819905 - J Agric Food Chem. 2006 Jul 12;54(14):4977-81
21820684 - Metabolism. 2012 Feb;61(2):202-12
20357372 - Diabetes Care. 2010 Jul;33(7):1509-15
11815489 - Diabetes. 2002 Feb;51 Suppl 1:S258-61
15955124 - Diabetes Obes Metab. 2005 Jul;7(4):381-9
21487493 - Nutr Res Pract. 2011 Feb;5(1):28-33
22560622 - Clin Ther. 2012 Jun;34(6):1221-36
12864749 - Acta Physiol Scand. 2003 Aug;178(4):435-42
21977461 - Diabetes Metab J. 2011 Aug;35(4):404-10
21763406 - Brain Res Bull. 2011 Aug 10;86(1-2):22-8
18238751 - Endocr Pract. 2008 Jan-Feb;14(1):112-24
22017960 - Br J Nutr. 2012 Jun;107(12):1757-65
20372175 - Eur J Clin Nutr. 2010 Jul;64(7):704-13
20125098 - Int J Obes (Lond). 2010 May;34(5):791-9
18326618 - Am J Clin Nutr. 2008 Mar;87(3):778-84
21470061 - Antioxid Redox Signal. 2011 Nov 15;15(10):2779-811
References_xml – issn: 2011
  publication-title: Nutritional sciences: from fundamentals to food
  doi: McGuire Beerman
– volume: 26
  start-page: 389S
  issue: 4
  year: 2007
  ident: c3fo60416k-(cit23)/*[position()=1]
  publication-title: J. Am. Coll. Nutr.
  doi: 10.1080/07315724.2007.10719627
– volume: 13
  start-page: 1
  issue: suppl. 1
  year: 2007
  ident: c3fo60416k-(cit17)/*[position()=1]
  publication-title: Endocr Pract
  doi: 10.4158/EP.13.S1.1
– volume: 54
  start-page: 4977
  issue: 14
  year: 2006
  ident: c3fo60416k-(cit11)/*[position()=1]
  publication-title: J. Agric. Food Chem.
  doi: 10.1021/jf0603681
– volume: 35
  start-page: 404
  year: 2011
  ident: c3fo60416k-(cit15)/*[position()=1]
  publication-title: J. Diabetes Metab.
  doi: 10.4093/dmj.2011.35.4.404
– volume: 57
  start-page: 1576
  issue: 11
  year: 2008
  ident: c3fo60416k-(cit21a)/*[position()=1]
  publication-title: Metab., Clin. Exp.
  doi: 10.1016/j.metabol.2008.06.014
– volume: 51
  start-page: 248
  year: 2005
  ident: c3fo60416k-(cit26)/*[position()=1]
  publication-title: J. Health Sci.
  doi: 10.1248/jhs.51.248
– volume: 6
  start-page: e615
  issue: 2–2
  year: 2011
  ident: c3fo60416k-(cit18)/*[position()=1]
  publication-title: Int. J. Pediatr. Obes.
  doi: 10.3109/17477166.2010.543684
– volume: 15
  start-page: 2779
  year: 2011
  ident: c3fo60416k-(cit8)/*[position()=1]
  publication-title: Antioxid. Redox Signaling
  doi: 10.1089/ars.2010.3697
– volume: 96
  start-page: 584
  issue: 3
  year: 2012
  ident: c3fo60416k-(cit10)/*[position()=1]
  publication-title: Am. J. Clin. Nutr.
  doi: 10.3945/ajcn.112.040469
– volume: 86
  start-page: 22
  issue: 1–2
  year: 2011
  ident: c3fo60416k-(cit9)/*[position()=1]
  publication-title: Brain Res. Bull.
  doi: 10.1016/j.brainresbull.2011.07.001
– volume: 2
  start-page: 737
  issue: 7
  year: 2010
  ident: c3fo60416k-(cit21b)/*[position()=1]
  publication-title: Nutrients
  doi: 10.3390/nu2070737
– volume: 51
  start-page: S258
  year: 2002
  ident: c3fo60416k-(cit16)/*[position()=1]
  publication-title: Diabetes
  doi: 10.2337/diabetes.51.2007.S258
– volume: 34
  start-page: 1221
  issue: 6
  year: 2012
  ident: c3fo60416k-(cit7)/*[position()=1]
  publication-title: Clin. Ther.
  doi: 10.1016/j.clinthera.2012.04.012
– volume: 7
  start-page: 381
  issue: 4
  year: 2005
  ident: c3fo60416k-(cit4)/*[position()=1]
  publication-title: Diabetes, Obes. Metab.
  doi: 10.1111/j.1463-1326.2004.00407.x
– volume: 2011
  start-page: 676208
  year: 2011
  ident: c3fo60416k-(cit27)/*[position()=1]
  publication-title: J. Nutr. Metab.
  doi: 10.1155/2011/676208
– volume: 33
  start-page: 1509
  issue: 7
  year: 2010
  ident: c3fo60416k-(cit6)/*[position()=1]
  publication-title: Diabetes Care
  doi: 10.2337/dc09-2191
– volume: 29
  start-page: 784
  issue: 11
  year: 2009
  ident: c3fo60416k-(cit14b)/*[position()=1]
  publication-title: Nutr. Res.
  doi: 10.1016/j.nutres.2009.10.003
– volume: 64
  start-page: 704
  issue: 7
  year: 2010
  ident: c3fo60416k-(cit12)/*[position()=1]
  publication-title: Eur. J. Clin. Nutr.
  doi: 10.1038/ejcn.2010.47
– volume: 86
  start-page: 128
  issue: 2
  year: 2011
  ident: c3fo60416k-(cit3)/*[position()=1]
  publication-title: Mayo Clin. Proc.
  doi: 10.4065/mcp.2010.0434
– volume: 7
  start-page: 1055
  issue: 8
  year: 2006
  ident: c3fo60416k-(cit5)/*[position()=1]
  publication-title: Expert Opin. Pharmacother.
  doi: 10.1517/14656566.7.8.1055
– volume: 67
  start-page: 1307
  year: 2012
  ident: c3fo60416k-(cit24)/*[position()=1]
  publication-title: J. Gerontol., Ser. A
  doi: 10.1093/gerona/glr235
– volume: 61
  start-page: 202
  issue: 2
  year: 2012
  ident: c3fo60416k-(cit19)/*[position()=1]
  publication-title: Metab., Clin. Exp.
  doi: 10.1016/j.metabol.2011.06.008
– volume: 178
  start-page: 435
  issue: 4
  year: 2003
  ident: c3fo60416k-(cit28)/*[position()=1]
  publication-title: Acta Physiol. Scand.
  doi: 10.1046/j.1365-201X.2003.01164.x
– volume: 87
  start-page: 778
  issue: 3
  year: 2008
  ident: c3fo60416k-(cit20)/*[position()=1]
  publication-title: Am. J. Clin. Nutr.
  doi: 10.1093/ajcn/87.3.778
– volume: 63
  start-page: 483
  issue: 4
  year: 2012
  ident: c3fo60416k-(cit22a)/*[position()=1]
  publication-title: Int. J. Food Sci. Nutr.
  doi: 10.3109/09637486.2011.636346
– volume: 589
  start-page: 4615
  issue: 18
  year: 2011
  ident: c3fo60416k-(cit14a)/*[position()=1]
  publication-title: J. Physiol.
  doi: 10.1113/jphysiol.2011.209924
– volume: 5
  start-page: 28
  issue: 1
  year: 2011
  ident: c3fo60416k-(cit25)/*[position()=1]
  publication-title: Nutr. Res. Pract.
  doi: 10.4162/nrp.2011.5.1.28
– volume: 34
  start-page: 791
  issue: 5
  year: 2010
  ident: c3fo60416k-(cit13)/*[position()=1]
  publication-title: Int. J. Obes.
  doi: 10.1038/ijo.2010.5
– volume: 14
  start-page: 112
  issue: 1
  year: 2008
  ident: c3fo60416k-(cit2)/*[position()=1]
  publication-title: Endocr Pract
  doi: 10.4158/EP.14.1.112
– volume: 107
  start-page: 1757
  issue: 12
  year: 2012
  ident: c3fo60416k-(cit22b)/*[position()=1]
  publication-title: Br. J. Nutr.
  doi: 10.1017/S0007114511005083
– reference: 22098442 - Int J Food Sci Nutr. 2012 Jun;63(4):483-90
– reference: 21270290 - Mayo Clin Proc. 2011 Feb;86(2):128-38
– reference: 11815489 - Diabetes. 2002 Feb;51 Suppl 1:S258-61
– reference: 21470061 - Antioxid Redox Signal. 2011 Nov 15;15(10):2779-811
– reference: 22219517 - J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12
– reference: 18940397 - Metabolism. 2008 Nov;57(11):1576-83
– reference: 18326618 - Am J Clin Nutr. 2008 Mar;87(3):778-84
– reference: 22254051 - Nutrients. 2010 Jul;2(7):737-51
– reference: 19932867 - Nutr Res. 2009 Nov;29(11):784-93
– reference: 21788351 - J Physiol. 2011 Sep 15;589(Pt 18):4615-31
– reference: 21977461 - Diabetes Metab J. 2011 Aug;35(4):404-10
– reference: 17906192 - J Am Coll Nutr. 2007 Aug;26(4):389S-395S
– reference: 20372175 - Eur J Clin Nutr. 2010 Jul;64(7):704-13
– reference: 20357372 - Diabetes Care. 2010 Jul;33(7):1509-15
– reference: 17613449 - Endocr Pract. 2007 May-Jun;13 Suppl 1:1-68
– reference: 21773023 - J Nutr Metab. 2011;2011:676208
– reference: 21244226 - Int J Pediatr Obes. 2011 Jun;6(2-2):e615-21
– reference: 22017960 - Br J Nutr. 2012 Jun;107(12):1757-65
– reference: 20125098 - Int J Obes (Lond). 2010 May;34(5):791-9
– reference: 18238751 - Endocr Pract. 2008 Jan-Feb;14(1):112-24
– reference: 12864749 - Acta Physiol Scand. 2003 Aug;178(4):435-42
– reference: 21763406 - Brain Res Bull. 2011 Aug 10;86(1-2):22-8
– reference: 16819905 - J Agric Food Chem. 2006 Jul 12;54(14):4977-81
– reference: 16722815 - Expert Opin Pharmacother. 2006 Jun;7(8):1055-64
– reference: 21487493 - Nutr Res Pract. 2011 Feb;5(1):28-33
– reference: 22560622 - Clin Ther. 2012 Jun;34(6):1221-36
– reference: 22811444 - Am J Clin Nutr. 2012 Sep;96(3):584-90
– reference: 21820684 - Metabolism. 2012 Feb;61(2):202-12
– reference: 15955124 - Diabetes Obes Metab. 2005 Jul;7(4):381-9
SSID ssj0000399898
Score 2.202279
Snippet Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in...
SourceID pubmedcentral
proquest
pubmed
crossref
rsc
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 521
SubjectTerms acute effects
Adult
adults
biochemical pathways
blood glucose
Blood Glucose - metabolism
calorimetry
carbohydrate metabolism
Carbohydrate Metabolism - drug effects
Catechin - administration & dosage
chocolate
Fats - metabolism
Female
Humans
hyperglycemia
Hyperglycemia - drug therapy
Hyperglycemia - metabolism
hypertriglyceridemia
inflammation
lipid metabolism
lipid peroxidation
Male
overweight
Overweight - drug therapy
Overweight - metabolism
oxidative stress
respiratory quotient
risk
triacylglycerols
Triglycerides - blood
volunteers
Title Acute effects of an oral supplement of (−)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/24458104
https://www.proquest.com/docview/1502997228
https://www.proquest.com/docview/2352447581
https://pubmed.ncbi.nlm.nih.gov/PMC3947792
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa67oUXNC6DjIuMQIg9eDT35LEM1gFiINhG3yI7cbSKkERpitT-An4Nv5FznGtpJwEvUZsc10nPF_t89rkQ8swJYwyx9pmw-YhZYNAyTwiXRY4whCvkyIww3vnDmXN6Yb2b2tPB4FfPa2lRiqNwtTWu5H-0CudArxgl-w-abX8UTsBn0C8cQcNw_Csdj0Pc5e-5ZGCdCYy4n2OtTtns84MRyYDxM5mrgDf0nsQ9gjybl3mBYS0YxMgrV_OQFyK7WkaYQQLLSwNGEqyjAU1SNG-rzAKZcqdGXg9dCVzKmfet3BNMlYyYwlmzv9M_gT-j2povCrliX7B4i_quq8FvwgUw96SdKT7CI6_Y5SwJ66rJn2YJb72JL3kIU_AyqvwMjhO-gCfpVnc_L8QsYxO-BDNArQe__VG_CfUih251Xl5HUg2GBoYRgTU57Y_cdg-gZm8Utqug643ZYWRictXQjDNnBIbot74QaDb_rnACBo_t1UWR_8jF3VzaIbsG0BJjSHbH719NvraretADFuRs8uCa_suuN8w7XbdfN4I2mM2mg-5O0dSjUXbP-R65WRMWOq7Qd4sMZHqbaK9nsqTPaZ1VNqFnTVGHO-SnQiWtUUmzmPKUIipph0o8-4Id9hFJs5T2EUkBkdAyon1E0g6RFJpUiFRSHSJpg8i75OLkzfnxKavrfbDQ8vwSiJ5rSiAYQgjfjTxPCid2wby1Qt8JjdiRwnOkdKTOvTiOJBhd0nVcaAtw8_zYNffJMM1SeZ9QKwbaA1SaSywQIbiwvVAfRX7keDowEFMjh40CgrBOho81WZJAOWWYftDpTSNPW9m8SgGzVepJo8cARmjcduOpzBbzACiXgeHphne9jAE8CFNverpG7lW6b_tqQKMRdw0VrQBmiF-_ks6uVKZ407dc1zc0sg_4aeX7N32w_UKQR_HBtXfygNzoXtKHZFgWC_kIbPNSPK5fiN-no-tp
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+effects+of+an+oral+supplement+of+%28-%29-epicatechin+on+postprandial+fat+and+carbohydrate+metabolism+in+normal+and+overweight+subjects&rft.jtitle=Food+%26+function&rft.au=Guti%C3%A9rrez-Salme%C3%A1n%2C+Gabriela&rft.au=Ortiz-Vilchis%2C+Pilar&rft.au=Vacaseydel%2C+Claudia+M&rft.au=Rubio-Gayosso%2C+Ivan&rft.date=2014-03-01&rft.eissn=2042-650X&rft.volume=5&rft.issue=3&rft.spage=521&rft_id=info:doi/10.1039%2Fc3fo60416k&rft_id=info%3Apmid%2F24458104&rft.externalDocID=24458104
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6496&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6496&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6496&client=summon